Gastric Cancer
Advertisement
Surgical resection with curative intent is the primary therapy for gastric cancer, yet the 5-year survival rate is just 20%.
Patients with a DpR of ≥30% had a favorable survival time with nivolumab monotherapy as a later-line treatment.
For those with a PD-L1 CPS of 5 or higher who received the combination therapy, the median OS was not achieved.
Researchers investigated the potential of an anti-H Pylori treatment after radical gastrectomy to improve survival.
Individuals with MLH1, MSH2, and EpCAM PVs were found to have a higher risk of developing GC and DC at the age of 70 years.
Dr. Janjigian discusses how the agent - created with invariant natural killer t-cells - works in tandem with other therapies.
Dr. Janjigian describes the history behind nivolumab treatment, and the differences in initial results versus follow-up.
Results of the PANDA study show that atezo has an additive effect with chemo in eliciting tumor response in early G/GEJ.
The study investigated if avelumab and paclitaxel plus ramucirumab would constitute an effective second-line treatment.
Dr. Yelena Janjigian on the MATTERHORN Study: Durvalumab Plus FLOT in Gastric Cancer at ASCO GI 2024
Dr. Yelena Janjigian discusses the results of the phase 3 MATTERHORN study at ASCO GI 2024.At ASCO GI 2024, new research examined several treatment combinations to determine which combination may improve OS rates.
The combination of neoadjuvant/adjuvant pembrolizumab with FLOT is a feasible treatment with no new safety concerns.
The benefits of combination neoadjuvant and adjuvant chemotherapy and immune checkpoint inhibition are currently unknown.
Researchers sought to determine if a combination of sintilimab and first-line chemotherapy would improve survival rates.
The addition of afatinib was found to provide marginal survival benefits, and nivolumab provided a durable survival benefit.
Pembrolizumab is now approved with fluoropyrimidine- and platinum-containing chemo for patients with gastric or GEJ cancer.
A phase 3 trial sought to determine the impact of HIPEC on overall survival in patients after undergoing CRS.
The combined pCR and near-complete pathological response rate was 27% with durvalumab and 14% with chemotherapy alone.
Pranob Bhattacharya discusses zolbetuximab, a first-in-class investigational therapy for the treatment of gastric cancer.
Daily vitamin D3 supplementation was associated with reduced risk of relapse or death in digestive tract cancer.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.